Navigation Links
Vital Therapies Announces Presentation of ELAD(R) 'Artificial Liver' Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
Date:11/6/2007

BOSTON, Nov. 7 /PRNewswire/ -- Vital Therapies, Inc. (VTI), announced today data from two studies of the company's ELAD(R) (Extracorporeal Liver Assist Device) System were presented at the 2007 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, which was held November 2-6 in Boston, Mass.

-- Abstract (#91), "Interim results of Randomized Controlled Trial of

ELAD(R) in Acute on Chronic Liver Disease," was presented in a

parallel session on Monday, November 5th. This controlled, randomized

(2:1) clinical trial enrolled 69 patients with acute-on-chronic liver

failure in two protocols at two centers in Beijing, China. The first

49 patient protocol resulted in a 30 day transplant-free survival rate

of 50% in the controls and 87% in the treated group (p<0.01). The

second protocol, which had a shorter ELAD(R) treatment time, did not

reach statistical significance. Initial conclusions from this trial

demonstrated ELAD(R) is safe and effective in this patient population

when used with the longer treatment time.

-- Abstract (#855), "ELAD(R) Cellular and System Performance

Improvements," was a poster presentation detailing the metabolic

characteristics of the ELAD(R) cartridges in order to optimize

performance.

Terry Winters, Ph.D., Chairman and CEO said, "These data are consistent with our previous research and experience. ELAD is helping patients and the technology continues to be refined for optimum benefit. These are positive developments as we apply for marketing approval in China and advance our U.S. clinical program."

To date, only liver transplantation has been shown to increase survival. However, demand for liver transplantation far exceeds the supply of donor livers, creating a need for an alternative, lifesaving therapy such as ELAD(R). In China alone, an estimated 160 million
'/>"/>

SOURCE Vital Therapies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
2. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
3. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
4. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
5. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015 Research and ... of the "Surgical/Operating Microscopes Market by Application ... report to their offering.      ... market is poised to reach $806.6 million by ... CAGR of 12.3% from 2015 to 2020. , ...
(Date:5/29/2015)... 29, 2015  Eli Lilly and Company (NYSE: ... announced that they have entered into a clinical trial ... AstraZeneca,s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination ... antiangiogenic cancer medicine. The planned study will assess the ... tumors. The Phase I study is expected ...
(Date:5/28/2015)... Ind. , May 28, 2015 Zimmer ... that it has finalized agreements with buyers to divest ... Zimmer® Unicompartmental High-Flex Knee System assets, Biomet Discovery® Elbow ... agreements are in furtherance of Zimmer,s pending acquisition of ... Zimmer continues to work constructively with the Bureau ...
Breaking Medicine Technology:Surgical/Operating Microscopes Market by Application & End User - Global Forecast to 2020 for the $806 Million Industry 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 3Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 4Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 5Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 6
... Inc. (Nasdaq: NUVA ), a medical device company ... for the spine, announced today that Kevin O,Boyle, Chief ... the Oppenheimer 20th Annual Healthcare Conference at The Waldorf ... November 3, 2009. , A live webcast of the ...
... your stomach, relieve your wallet , YONKERS, N.Y., Oct. ... us may suffer from occasional heartburn, a new Best Buy Drugs ... don,t need an expensive drug like Nexium, the "purple pill," for ... to identify "Best Buys" based on safety, effectiveness, and price for ...
Cached Medicine Technology:NuVasive to Present at the Oppenheimer 20th Annual Healthcare Conference 2NuVasive to Present at the Oppenheimer 20th Annual Healthcare Conference 3Consumer Reports Health: Americans With Heartburn Paying Too Much Green For Nexium's 'Purple Pill' 2Consumer Reports Health: Americans With Heartburn Paying Too Much Green For Nexium's 'Purple Pill' 3
(Date:5/30/2015)... Alexandria, VA (PRWEB) May 30, 2015 ... Research Foundation interviewed Dr. Charles Simone and Dr. ... Medicine, during its ‘Meet the Mesothelioma Experts’ series. ... interviews focusing on mesothelioma centers of excellence. Drs. ... Foundation’s executive director, Mary Hesdorffer, with whom they ...
(Date:5/30/2015)... May 30, 2015 Responding to surging ... travelers who experienced OGAWA products while abroad, OGAWA-engineered massage ... , A leader in the Asian health and ... designer, researcher, developer and manufacturer of health and wellness ... craftsmanship of their products, health enthusiasts in Asia and ...
(Date:5/30/2015)... Cyclist Barry Haarde will commence ... World 2015: Piles of Miles” near San Francisco, ... hemophilia and encourage individuals to support needy hemophilic ... One Life supports nearly 1,200 impoverished children and ... direct sponsorships, scholarships and micro-enterprise grants. Hemophilia is ...
(Date:5/30/2015)... The iconic American actor, and host of “In ... segment on Medical Malpractice. This segment of “In America” ... health care field. , According to the Bureau of ... were filed, roughly only 20% of them made it ... while the remaining 30% were tossed out. (Source: ...
(Date:5/30/2015)... Venus Viva has proven to work ... deep wrinkles, stretch marks, pigmentation irregularities, and uneven texture ... Dr. F. Victor Rueckl of Lakes Dermatology in Las ... Las Vegas. This body image solution combines NanoFractional Radio ... delivers proven results through a skin heating process that ...
Breaking Medicine News(10 mins):Health News:Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 2Health News:Award-winning OGAWA Massage Chairs Finally Available for purchase in North America. 3Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 3
... study shows that people with a low potassium intake are ... Previous research has suggested that reduced quantities of potassium in ... focus on potassium is, perhaps, a new one - for ... intake low to avoid stroke. But sodium and potassium chemistry ...
... heart improves function in patients with advanced heart failure. Researchers ... failure, the heart enlarges and is unable to effectively pump ... too. Heart failure is a progressive condition, with no cure ... with medication. ,However, a new cardiac support device ...
... eases hand spasticity among stroke survivors. Spasticity in the limbs ... much disability,// because it interferes with activities like getting dressed ... a substance that relieves muscle tightness - may help with ... botulinum toxin (also known as botox) in stroke, a group ...
... new study, the the functionality of lungs can be well ... our early days. Scientists have long known a test called ... an effective measure of lung function and predictor of morbidity ... investigators have speculated factors like exposure to tobacco smoke during ...
... works better than relaxation in lessening the symptoms of ... of 120 patients diagnosed with fibromyalgia, a painful muscular ... the patients were initiated to routine sessions of graded ... ,After three months, more of those in the exercise ...
... research it is found that an enzyme that rectifies ... reducing a person's susceptibility to diseases such as hemophilia, ... Wales and the University of Edinburgh in Scotland have ... mutations that can lead to diseases. ,Different combinations ...
Cached Medicine News:
... Since 1991 Intersurgical Incorporated ... filters, heat and moisture ... therapy products, hand-held nebulizers ... of accessories and connectors ...
The Pall High Performance HME is a high efficiency heat and moisture exchanger, indicated to protect patients against the potential risks of ventilation with dry and cold gases....
Passive heat and moisture exchangers for respiratory applications....
Ballard trach care HMES and filters, tv 1500, HME with built-in flex tube...
Medicine Products: